Month: October 2016

Home » Archives for October 2016

A peek behind the curtain: pathologists are the most important doctors you’ll never meet

Unlike your GP, urologist, and oncologist, pathologists are not docs that you choose and you’ll likely never meet them. They are associated with labs and with medical practices. They rarely meet patients or speak to them. In fact, in some areas pathologists are barred from speaking to patients. An interview with Dr. Les Raff, head pathologist at UroPartners LLC in Chicago. Read the article here.

Preventing Overtreatment of Prostate Cancer: New Model Identifies Ideal Patients for Active Surveillance

A new care model for patients with low-risk prostate cancer may help prevent disease overtreatment. This evidence-based approach uses best practices to select patients to avoid disease overtreatment. Results from a 3-year study recently published in Urology indicate that active surveillance (AS) rates nearly doubled after this model was adopted. Read the article here.

Hamilton study a “game changer” for prostate cancer treatment

A “game changer” study has concluded many prostate cancer patients need half as much radiation treatment as currently given. Ontario hospitals are already starting to change treatment to four weeks from the standard eight because of the study led by Hamilton’s Juravinski and Toronto’s Princess Margaret cancer centres. Read the article here.

Laser ablation becomes increasingly viable treatment for prostate cancer

Up until now, capturing an image of a prostate cancer has been difficult because prostate tissue and tumor tissue are so similar. Precise, non-invasive surgical treatment has proved difficult as a result. Now UCLA researchers report that prostate cancer patients may soon have a new option to treat their disease: laser heat. Read the article here.

Lawson Health scientists capture prostate cancer images using unique molecule

Scientists at Lawson Health Research Institute in London are the first in Canada to capture prostate cancer images using a new molecule. Known as a Prostate Specific Membrane Antigen (PSMA) probe, the new molecule is used in Positron Emissions Tomography (PET) scans. The probe targets PSMA, a unique molecule on prostate cancer cells, to provide highly specific images for better diagnosis and management of patient disease. Read the article here.

Scroll to Top